MX2019004345A - Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida. - Google Patents

Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida.

Info

Publication number
MX2019004345A
MX2019004345A MX2019004345A MX2019004345A MX2019004345A MX 2019004345 A MX2019004345 A MX 2019004345A MX 2019004345 A MX2019004345 A MX 2019004345A MX 2019004345 A MX2019004345 A MX 2019004345A MX 2019004345 A MX2019004345 A MX 2019004345A
Authority
MX
Mexico
Prior art keywords
crystalline forms
hydroxycyclohexylamino
benzothiazol
yloxy
methylpicolinamide
Prior art date
Application number
MX2019004345A
Other languages
English (en)
Spanish (es)
Inventor
Grandeury Arnaud
Murlidhar Waykole Liladhar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019004345A publication Critical patent/MX2019004345A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MX2019004345A 2016-10-14 2017-10-13 Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida. MX2019004345A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662408358P 2016-10-14 2016-10-14
PCT/IB2017/056379 WO2018069892A1 (en) 2016-10-14 2017-10-13 Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide

Publications (1)

Publication Number Publication Date
MX2019004345A true MX2019004345A (es) 2019-07-01

Family

ID=60320932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004345A MX2019004345A (es) 2016-10-14 2017-10-13 Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida.

Country Status (14)

Country Link
US (1) US10934273B2 (enExample)
EP (1) EP3526217B1 (enExample)
JP (1) JP7068288B2 (enExample)
KR (1) KR20190064589A (enExample)
CN (1) CN109843880B (enExample)
AU (1) AU2017342239B2 (enExample)
BR (1) BR112019006914A2 (enExample)
CA (1) CA3039764A1 (enExample)
CL (1) CL2019001008A1 (enExample)
ES (1) ES2949414T3 (enExample)
IL (1) IL265893A (enExample)
MX (1) MX2019004345A (enExample)
RU (1) RU2019114208A (enExample)
WO (1) WO2018069892A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
CA3162315A1 (en) * 2019-12-20 2021-06-24 Marinus Jacobus Verwijs Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
PE20080359A1 (es) * 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
CA2834696C (en) * 2011-05-05 2019-07-23 Novartis Ag Csf-1r inhibitors for treatment of brain tumors
WO2016100882A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Combination therapies

Also Published As

Publication number Publication date
CN109843880A (zh) 2019-06-04
EP3526217A1 (en) 2019-08-21
US20200190057A1 (en) 2020-06-18
IL265893A (en) 2019-06-30
CN109843880B (zh) 2023-12-01
WO2018069892A1 (en) 2018-04-19
RU2019114208A3 (enExample) 2020-11-18
JP2019530719A (ja) 2019-10-24
EP3526217B1 (en) 2023-04-19
CL2019001008A1 (es) 2019-06-21
CA3039764A1 (en) 2018-04-19
KR20190064589A (ko) 2019-06-10
AU2017342239B2 (en) 2020-05-28
JP7068288B2 (ja) 2022-05-16
BR112019006914A2 (pt) 2019-07-02
US10934273B2 (en) 2021-03-02
RU2019114208A (ru) 2020-11-16
ES2949414T3 (es) 2023-09-28
AU2017342239A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
SA519401020B1 (ar) مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
EA201891526A3 (ru) Ингибиторы лизин-специфической деметилазы-1
PH12018501084B1 (en) Heterocyclic compounds as immunomodulators
MX2015013481A (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
PH12015501868A1 (en) Inhibitors of histone demethylases
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
PH12019501896A1 (en) Therapeutic dendrimers
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2019004345A (es) Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida.
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
PH12017501134A1 (en) Fumagillol derivatives
PE20170522A1 (es) Forma polimorfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzheimer
EA201990556A1 (ru) Ингибиторы клеточных метаболических процессов